Apposite Capital

Apposite Capital solely focuses on healthcare. They work closely with management teams; providing operational support and strategic guidance as much as capital to together build market leading companies. They invest in high potential revenue-generating companies across Europe. They tailor their investment to each company’s needs and consider all types of financing structures (minority, growth, buyout, buyin, etc). They typically seek to invest £10-20 million over the life of each investment but an initial investment can be £5 million or less.

Steve Adkin

Portfolio Director

Valerie Auffray

Head of Investor Relations and Operations

AC

Alexander Cunymghame

Investment Manager

AC

Alex Cunynghame

Investment Manager

Alexander Cunynghame

Investment Manager

LE

Lauren Edison

Investment Manager

Sam Gray

Managing Partner

JH

James Harper

CFO

AM

Anne-Laure Meynier

Investment Director

Rory Pope

Partner

David Porter

Founding Partner

Christian Schenk

Investment Manager

26 past transactions

PharmaKodex

Series A in 2006
PharmaKodex is a pharmaceutical company that develops and commercializes small molecule drugs for treating pain and neurological conditions. The company was founded in 2006 and is based in Cambridge, the United Kingdom with an additional office in Chippenham, the United Kingdom. As of February 23, 2009, PharmaKodex Ltd. operates as a subsidiary of Orexo AB.

Medical Imaging Partnership

Venture Round in 2016
Medical Imaging Partnership has been created by UK Radiologists to offer high-quality radiology services to both Private and NHS Patients. Medical Imaging Partnership's goal is to give both Patients and Referrers fast access to expert-led services. Medical Imaging Partnership offers an unparalleled service to Healthcare Professionals and Patients with reports by leading specialist Radiologists. Medical Imaging Partnership is accredited by all of the major private medical insurers and offer a competitive self-pay price.

Mirada Medical Limited

Private Equity Round in 2022
Mirada Medical is a prominent global brand in medical imaging software. Mirada’s innovative software solutions are routinely used in radiology, molecular imaging, radiation oncology and in multidisciplinary meetings throughout hospitals, imaging centers and cancer centers worldwide. Mirada excels at combining scientifically advanced technology with practical application for diagnosis, management and treatment of cancer and other diseases. - See more at: http://www.mirada-medical.com/about-mirada-medical/#sthash.Sp4rzAG0.dpuf

Ambit Biosciences

Series D in 2011
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Enara Group

Acquisition in 2017
Enara provides high quality home care in the UK, delivering a wide range of services to people who require help and support due to illness, disability or infirmity. The business cares for people via local authority, NHS and private pay agreements.

1MED

Acquisition in 2021
1MED is a full service CRO offering clinical research services and solutions for all clinical trials' needs.

Bird Rock Bio, Inc.

Series A in 2009
Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Anaphore

Series A in 2009
Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Prime Health Diagnostics Ltd

Acquisition in 2018
Prime Health Diagnostics Ltd operates as a diagnostic, treatment, and fitness facility. It offers medical and diagnostics services, such as consultant clinics, private GP, 3T MRI, ultrasound, and X-ray; and therapy and fitness services, including physiotherapy and osteopathy, personal training, Pilates, nutritional therapy, podiatry, sports massage, performance coaching, and complementary therapy. The company was incorporated in 2010 and is based in Weybridge, United Kingdom.

SureCalm Healthcare

Acquisition in 2010
SureCalm Healthcare focuses on providing high quality homecare to patients who are managing long term conditions on a daily basis. The group aims to provide a comprehensive range of healthcare services to patients in the home setting, and specialises in dispensing stoma care and continence devices, home delivery, individual care services and a newly launched internet and mail order pharmacy business providing clients with all their medicine requirements and advice.

Ambrx, Inc.

Series C in 2006
Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.
Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSK”). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.

Ulthera

Series C in 2011
Ulthera is an emerging ultrasound-based medical technology company that is raising the bar for aesthetic medical procedures. While the demand and promise for noninvasive energy-based procedures continue to grow, the ability to consistently deliver safe, significant, and satisfying results has been elusive. Ulthera is a company dedicated to achieving these types of results through elective medical procedures for rejuvenation of the skin and its underlying tissue. The Ulthera® System, with its patented DeepSEE™ technology, is an engineering triumph that has adapted the imaging and therapy capabilities of time-honored medical ultrasound to address the unmet needs of the aesthetic marketplace. What began as an exploration of image-guided cancer therapy evolved over seven years into the founding of Ulthera, Inc.

OrthoD Group Ltd.

Acquisition in 2018
Summit Medical Group Limited manufactures and markets medical products such as sports medicine, surgical products, and infection control products. It offers reconstruction devices, sports medicine implants and instruments, and operation theatre accessories; autologous blood transfusion systems, bone cement and delivery systems and accessories, exsanguinating sterile tourniquets, and wound drains. Summit Medical Group Limited was formerly called OrthoD Group Ltd. and changed its name to Summit Medical Group Limited in April 2019. The company was founded in 1984 and is based in Cheltenham, United Kingdom with operations in the United Kingdom and France.

Anaphore

Series A in 2009
Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Mirada Medical Limited

Private Equity Round in 2019
Mirada Medical is a prominent global brand in medical imaging software. Mirada’s innovative software solutions are routinely used in radiology, molecular imaging, radiation oncology and in multidisciplinary meetings throughout hospitals, imaging centers and cancer centers worldwide. Mirada excels at combining scientifically advanced technology with practical application for diagnosis, management and treatment of cancer and other diseases. - See more at: http://www.mirada-medical.com/about-mirada-medical/#sthash.Sp4rzAG0.dpuf

Complete Care

Acquisition in 2017
Complete Care provides high acuity care at home to around 150 individuals with on-going complex clinical healthcare needs. The business employs around 650 personal care assistants (including registered nurses). This acquisition will complement Mitie’s existing domiciliary care operations in England and Wales, which are primarily operated through MiHomecare.

Bird Rock Bio, Inc.

Series B in 2014
Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.
Swanton, a specialist provider of residential and supported living care for adults with complex learning disabilities, mental health disorders and acquired brain injuries. Swanton operates 24 specialist residential care homes, providing 259 registered beds across East Anglia, The West Midlands and South West Wales, the North East and Scotland. Swanton also provides a growing supported living service in its key localities. The company employs around 780 people and generated £25m revenues in the year end.

Archway Dental Practice

Acquisition in 2019
Archway Dental Practice Limited provides dentistry services to private patients in Dursley and Stroud, United Kingdom. The company was founded in 1996 and is headquartered in Dursley, United Kingdom. As of September 3, 2019, Archway Dental Practice Limited operates as a subsidiary of Riverdale Healthcare Limited.

Serentis

Series A in 2007
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

Ambit Biosciences

Venture Round in 2012
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Serentis

Series A in 2008
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

MiHomecare

Acquisition in 2017
MiHomecare provide a wide range of homecare services to people who need help and support, whether due to old age, illness, disability or infirmity.

Cancer Partners UK

Venture Round in 2013
Cancer Partners UK provides the highest levels of patient-focused care across a network of conveniently located, purpose-built cancer centres. Each centre has been individually designed to meet the needs of the local area and falls into one of three centre types. As such, each varies in what services are offered, but each centre aspires to the same core principles and provides the same high quality standard of patient services. From the moment a patient is referred by their GP, they have prompt access to diagnostic procedures and tests, as well as treatments including advanced radiotherapy, chemotherapy and hormone therapy, all ‘under one roof’.

NIMGenetics

Venture Round in 2017
NIMGenetics es un Centro de Diagnóstico analítico con unidad de Genética autorizado por la Consejería de Sanidad de la Comunidad de Madrid. Nuestro equipo científico-médico acreditado profesional y científicamente por la Asociación Española de Genética Humana, está especializado en el desarrollo y aplicación de sistemas genómicos de alta resolución, para la realización de un diagnóstico clínico fiable y preciso.